Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
25 Février 2015 - 10:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that
William Lis, chief executive officer, will present at the Cowen and
Company 35th Annual Health Care Conference on Tuesday, March 3,
2015 at 8:40 a.m. Eastern Time in Boston.
The presentation will be webcast live and available for replay
from Portola's website at www.portola.com in the Investor Relations
section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing its three wholly-owned programs using novel biomarker and
genetic approaches that may increase the likelihood of clinical,
regulatory and commercial success of its potentially life-saving
therapies. Portola's partnered program is focused on developing
selective Syk inhibitors for inflammatory conditions.
Betrixaban
Portola's wholly-owned, oral, once-daily Factor Xa inhibitor
betrixaban is being evaluated in the only biomarker-based Phase 3
study for hospital-to-home prophylaxis of venous thromboembolism
(VTE) in acute medically ill patients. Betrixaban's distinct
properties may have the potential to allow the agent to demonstrate
efficacy without the significant increase in the rate of major
bleeding that was seen in this patient population with other Factor
Xa inhibitors. If approved, betrixaban could be the first
anticoagulant for both hospital and post-discharge VTE prophylaxis
and the standard of care in this large market of more than 20
million patients in the G7 countries alone.
Andexanet Alfa
Andexanet alfa, an FDA-designated breakthrough therapy, is a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor.
Andexanet alfa has the potential to be a first-in-class antidote
for anticoagulated patients who suffer a major bleeding episode or
require emergency surgery. Portola has entered into Phase 3
clinical collaboration agreements with all of the manufacturers of
direct Factor Xa inhibitors – Bristol-Myers Squibb and Pfizer
(Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals
(XARELTO® [rivaroxaban]), and Daiichi Sankyo (edoxaban) – while
retaining all commercial rights to andexanet alfa. The Company is
currently evaluating andexanet alfa in the Phase 3 and Phase 4
ANNEXA™ (Andexanet Alfa a Novel Antidote to the Anticoagulant
Effects of fXA Inhibitors) registration studies.
Cerdulatinib
Portola's product candidate in the area of hematologic cancer,
cerdulatinib, is an orally available molecule that uniquely
inhibits two validated tumor proliferation pathways – spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
evaluated in a Phase 1/2a proof-of-concept study in patients with B
cell leukemias or lymphomas with a focus on genetically-defined
subtypes, as well as in patients who have failed therapy due to
relapse or acquired mutations.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
CONTACT: Portola
Media:
Joey Fleury, BrewLife
jfleury@brewlife.com, 415.946.1090
Investors:
Alexandra Santos, Portola Pharmaceuticals
ir@portola.com, 650.246.7239
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024